Detail akcie Cortexyme Rg online

Business Summary: Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Quince Therapeutics Inc revenues was not reported. Net loss decreased less than 1% to $44.5M. Net income also reflects Developing and commercializing therapeutics segment loss decrease of 47% to $23.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.03 to -$0.94.